Stem Cell Transplantation: It’s Time!
Australian scientists from Monash
Christopher Siatskas, Natalie Payne and Prof Claude Bernard, provide commentary
on the development of a recent consensus statement from world experts on stem
cells for the treatment of MS:
is a neurodegenerative disease of the central nervous system that includes the
brain and spinal cord. The disease is characterized by inflammation,
demyelination and clinical relapses. Current therapeutic interventions for MS
reduce the inflammation but have little effect on the underlying
neurodegeneration that usually leads to increasing disability over the long
stem cells (MSCs) which are endowed with potent properties to influence and
protect the immune system have recently emerged as promising opportunity for
the treatment of MS. Early tests in experimental models have shown that MSCs
can suppress MS to limit CNS inflammation, stimulate neuron growth, protect
specific parts of a neuron called the axon and promote remyelination.
transplantation with MSCs have been well tolerated by patients with few
significant adverse effects. On the basis of these results, new, multicentre
clinical trials have been launched overseas to assess the safety and efficacy
of MSCs for inflammatory MS.
it comes as no surprise that the coalescence of an international group of
experts have convened to generate a consensus guide for the transplantation of
bone marrow-derived MSC which, in time, may set the foundation for the next
generation of therapies for the treatment of MS.
Stem Cell Rev. 2010 Jul 28, Siatskas C, Payne NL, Short MA, Bernard CC
Natalie Payne is a
Postgraduate Research Scholar funded by the Trish Foundation.